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The mixed message of hope
and danger emanating from this
case is reflected in variable
enthusiasm for gene therapy
around the globe. In Germany,
where the research ministry has
cautiously supported such
research since 1994, Ärzte
Zeitung estimates that around 250
patients are currently undergoing
experimental treatment involving
gene transfer. All such trials must
be approved by the ‘Kommission
Somatische Gentherapie’, an
expert committee formed by the
scientific advisory board of the
federal chamber of physicians
(Bundesärztekammer). After the
bad news from Paris broke, the
committee halted all studies
involving retroviruses for a careful
reassessment of the risk situation.
By now it seems certain that most
of the studies will be continued.
Only one, which was to target
granulomatosis, is still blocked
indefinitely.
In the United States, a new
gene therapy trial targeting age-
dependent macula degeneration
has been given the go-ahead in
February. It will initially involve
around 50 patients. In Britain, a
smaller scale trial of X-SCID gene
therapy, similar to the one at
Paris, funded by the ‘Jeans for
Genes’ campaign, has been
carried out at Great Ormond
Street Hospital in London. It
reported its first cure in April 2002.
At the beginning of this year, the
study was suspended for a few
months, but is now set to
continue.
Meanwhile, the UK government
has published an official report
(‘White Paper’) on genetics,
entitled ‘Our inheritance - our
future: Realising the potential of
genetics in the NHS’ with plans of
incorporating recent advances in
genetics into the mainstream
healthcare offered by the National
Health Service (NHS). The paper,
prepared by the former Health
Secretary Alan Milburn and
presented by his successor John
Reid, comprises the search for
new treatments, including gene
therapy, alongside with enhanced
antenatal screening, genetics-
related counselling, knowledge
transfer measures, and legislation
against DNA theft (see sidebar).
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The paper pronounces with
cautious optimism that gene
therapy might become available
within five to ten years from now.
It pledges government investment
of £3 million for gene therapy
research targeting disorders
caused by mutations of a single
gene, and an extra £2.5 million,
spread out over five years, to
develop a gene transfer therapy
against cystic fibrosis, the most
common such disease in Britain. A
further £4 million (of £50 million for
the entire genetics initiative) are
earmarked to give NHS and other
public sector researchers access
to facilities where suitable vectors
for gene therapy can be
produced.
While researchers everywhere
have been sobered by the
leukemia cases and may in some
cases be forced to reconsider
their use of retroviral vectors, the
search for the right way of curing
the genes causing severe
disorders such as X-SCID and
cystic fibrosis goes on. Getting it
right will not be simple, and it will
probably be more expensive than
the UK government seems to
think. But it will be truly
revolutionary.
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the UK’s latest media frenzy over
genetically modified (GM) foods
was triggered in precisely the
opposite way. It began with a
newspaper article by a former
minister on a subject for which he
was until very recently
responsible.
“Blair buried health warning on
GM crops, says sacked minister”
was the banner headline which
launched the piece by Michael
Meacher in The Independent on
Sunday. The former Environment
Minister criticised Prime Minister
Tony Blair for (allegedly)
contravening his own policy that
the debate should be conducted
on the basis of scientific evidence
rather than prejudice. Yet nothing
in the article supported that
allegation.
Meacher cited a claim that GM
technology “often involves
producing novel substances
which may provoke allergic
reactions”. In the real world, of
course, its major promise is in
deleting genes coding for
allergens. The only “scientific
evidence” cited by Meacher was
from experiments when a known
allergen gene was transferred
from brazil nuts to soya — which
then provoked adverse reactions
in subjects already known to be
allergic to brazil nuts.
Meacher also asserted that
Arpad Pusztai's “work on rats and
GM potatoes...was widely
rubbished in government circles
even though his paper had been
peer reviewed six times before
publication.” Given that Pusztai’s
claims five years ago of adverse
effects on growth and the immune
system have never appeared in a
peer-reviewed journal, this is a
travesty of reality. Even the paper
which he did co-author (on the
structure of the small intestine)
appeared against peer review
advice (Curr. Biol. (1999) 9, R794).
Among many other distortions,
Meacher quoted selectively from a
Royal Society report that GM
could “lead to unpredictable
harmful changes in the nutritional
state of foods”. Of course it could.
But as Lord May, president of the
society, said in The Independent
three days later, Meacher
“conspicuously fails to mention its
principal conclusion that there is
no scientific reason to doubt the
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Mediawatch: Parts of the British media are keeping up a campaign
against the introduction of genetically modified crops ahead of the
government’s assessment of the trial programme this autumn, often to
the detriment of the arguments, writes Bernard Dixon.
safety of foods made from GM
ingredients that are currently
available, nor to believe that
genetic modification makes GM
foods inherently less safe than
conventional counterparts”. 
Meanwhile, the Daily Mail had
launched a “Frankenstein Food
Watch” campaign by attacking
comments made by Meacher’s
successor, Elliot Morley. “A
minister used flawed evidence
yesterday to claim that eating GM
foods is safe,” wrote consumer
affairs correspondent Sean
Poulter under the headline “GM:
Has the truth been genetically
modified?” According to Poulter,
two studies cited by Morley as
showing the safety of GM food
“turned out to be academic and
theoretical reviews of old
material”. What, one wonders, did
readers make of that?
In parallel with these exchanges
on (alleged) food toxicity,
disputation resurfaced on
environmental issues. “GM crops
could carpet Britain with
superweed,” announced the Daily
Mail. “Superweeds signal setback
for GM crops” said The
Independent, reporting “the
evolution of superweeds which
are resistant to the powerful
weedkillers that GM crops were
engineered to tolerate”. 
However, closer reading of
these reports showed a rather
different picture. Thus The
Independent’s article, by
environment editor Michael
McCarthy, was about the recent
emergence of weeds insensitive
to the Monsanto herbicide
Roundup (glyphosate). Yet he
himself recognized that “the
resistance has come about not
through gene transfer from GM
herbicide-tolerant crops, as some
have feared, but through natural
evolution”.
As has often happened during
the GM debate, several of the
sharpest comments on this topic
appeared not in the news
columns but in readers’ letters.
“Yes, we do have superweeds:
you can buy them in any garden
centre (try Japanese knotweed,
Australian swamp stonecrop or
floating pennywort) together with
the ‘powerful weedkillers’
needed to control them,” wrote
Mike Bayliss in The Independent.
“We should be using plant
breeding and genetic
modification, which all the
evidence shows will minimise
chemical inputs and maximise
sustainable production from
intensively farmed land.” 
A third ingredient in the recent
furore came from a report issued
by the Prime Minister's Strategy
Unit. This was widely portrayed,
especially on television, as
showing that GM crops offered no
inherent economic benefits to
either producers or consumers.
Coupled with claims regarding
their toxicity and environmental
dangers, this was presented as a
threat to the continuance of GM
food work.
The calmer truth appeared in
The Times, which reported the
Strategy Unit as arguing that
“although GM crops could offer
cost and convenience advantages
to British farmers, public
attitudes...would stop them
reaching supermarket shelves in
the short term”. Research should
go ahead “despite the limited
short-term commercial
prospects”, while long-term
benefits may include foods with
added nutrients. The report also
highlighted GM plants as sources
of pharmaceuticals and vaccines,
as well as a future market for
animal feeds.
Yet even The Times used as its
headline “GM crops offer little
economic benefit”. The article
appeared alongside a photograph,
almost equal in size, showing
“Barewitness” - a group of
protestors spelling out “NO GM”
with their naked bodies in a field
in Sussex. Pictures, we should
remember, invariably speak louder
than words. 
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Seeds of contention: Parts of the British media continue their campaign against genetically modified crops. A trial of GM oilseed rape
is being examined by a researcher near King’s Lynn in Norfolk, UK. (Photograph: Chris Knapton/Science Photo Library.)
